Despite the initial response to ADT in the hormone-naïve setting, which usually achieves rapid decline in PSA levels, this therapy does not completely wean tumor cells of androgens because prostate cancer cells can employ alternative routes to generate AR ligands [44]. This evidence concerns the gene KLK3 and Familial prostate cancer.